Immunotherapy and chemo before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests the safety and effectiveness of combining two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (nab-paclitaxel) before surgery for people with a certain type of esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of esophageal cancer called squamous cell carcinoma that is locally advanced (has spread to nearby lymph nodes but not to other organs) and can be removed with surgery.
- You cannot have had any previous treatment for this cancer.
- You must be in generally good health, with adequate blood counts and liver, kidney, and heart function.
- You cannot have an active autoimmune disease, serious infection (like HIV or hepatitis), or another cancer in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug adebrelimab to a short course of chemo and radiation before surgery can improve outcomes for patients with resectable esophageal cancer. It is designed for people with a specific stage of esophageal squamous cell carcinoma that has not been treated before.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and lenvatinib before surgery to treat esophageal squamous cell carcinoma that hasn't spread and can be removed. It aims to see if this approach can improve outcomes for patients with stage II to IVa disease.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.